JAMP-SILDENAFIL TABLET

국가: 캐나다

언어: 영어

출처: Health Canada

지금 구매하세요

제품 특성 요약 제품 특성 요약 (SPC)
06-05-2013

유효 성분:

SILDENAFIL (SILDENAFIL CITRATE)

제공처:

JAMP PHARMA CORPORATION

ATC 코드:

G04BE03

INN (International Name):

SILDENAFIL

복용량:

50MG

약제 형태:

TABLET

구성:

SILDENAFIL (SILDENAFIL CITRATE) 50MG

관리 경로:

ORAL

패키지 단위:

4

처방전 유형:

Prescription

치료 영역:

PHOSPHODIESTERASE TYPE 5 INHIBITORS

제품 요약:

Active ingredient group (AIG) number: 0136261002; AHFS:

승인 상태:

CANCELLED POST MARKET

승인 날짜:

2022-09-07

제품 특성 요약

                                _Jamp-SILDENAFIL (Sildenafil Citrate Tablets) 25 mg, 50 mg, 100 mg _
_Page 1 of 44_
_ _
PRODUCT MONOGRAPH
PR JAMP-SILDENAFIL
sildenafil (as sildenafil citrate) tablets
25 mg, 50 mg and 100 mg
cGMP-Specific Phosphodiesterase Type 5 Inhibitor
Treatment of Erectile Dysfunction
SPONSOR:
Jamp Pharma Corporation
DATE OF PREPARATION:
1380-203 Newton
April 24, 2013
Boucherville, Québec
J4B 5H2
SUBMISSION CONTROL NO: 163804
_Jamp-SILDENAFIL (Sildenafil Citrate Tablets) 25 mg, 50 mg, 100 mg _
_Page 2 of 44_
_ _
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION................................................3
SUMMARY PRODUCT INFORMATION
.........................................................................3
INDICATIONS AND CLINICAL
USE................................................................................3
CONTRAINDICATIONS
.....................................................................................................3
WARNINGS AND
PRECAUTIONS....................................................................................4
ADVERSE
REACTIONS......................................................................................................7
DRUG INTERACTIONS
....................................................................................................10
DOSAGE AND
ADMINISTRATION................................................................................13
OVERDOSAGE
..................................................................................................................14
ACTION AND CLINICAL PHARMACOLOGY
..............................................................15
STORAGE AND
STABILITY............................................................................................18
SPECIAL HANDLING INSTRUCTIONS
.........................................................................18
DOSAGE FORMS, COMPOSITION AND PACKAGING
...............................................18
PART II: SCIENTIFIC INFORMATION
.....................................................................
                                
                                전체 문서 읽기
                                
                            

다른 언어로 된 문서

제품 특성 요약 제품 특성 요약 프랑스어 06-05-2013

이 제품과 관련된 검색 알림